New and Noteworthy
Explore our latest insights, research, and stories
All the latest
Showing 9 of 0 results
- Comparative overall survival of CDK4/6is plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting
San Antonio Breast Cancer Symposium
- Tolerability of first-line treatment with ribociclib for metastatic breast cancer using two large US data sources
San Antonio Breast Cancer Symposium